Without the proper trust when so much is at stake, study sites will not be able to get willing patients in the door.
Several recent corporate partnerships have formed to further the development and conduct of clinical trials.
Sites should avoid relying on sponsors when implementing quality policies, expert warns. “Each sponsor will tell you something different” and the result can be a complex mess.
“DCTs are here to stay. PI oversight is even more important now.”
A highly anticipated trial in sub-Saharan Africa is the first to specifically evaluate the efficacy of a COVID-19 vaccine in people living with HIV.